Omega-7 fatty acids

Omega-7 Fatty Acids

1. Identity: Chemical Names, Structure, and Classification

Omega-7 fatty acids (also referred to as ω−7 fatty acids or n−7 fatty acids) are a class of unsaturated fatty acids in which the site of unsaturation is seven carbon atoms from the end of the carbon chain. The two most common omega-7 fatty acids in nature are palmitoleic acid and vaccenic acid.

Palmitoleic acid, or (9Z)-hexadec-9-enoic acid, is an omega-7 monounsaturated fatty acid (16:1n-7) with the formula CH₃(CH₂)₅CH=CH(CH₂)₇COOH. It belongs to the group of unsaturated fatty acids, having one cis double bond from the methyl end in the omega-7 (ω-7) or n-7 position; it is also a member of the subgroup called long-chain fatty acids (LCFA), which spans from 14 to 18 carbon atoms.

Palmitoleic acid also exists in a trans form (known as trans-palmitoleic acid, 9-trans-palmitoleic acid, or (E)-9-hexadecanoic acid), which demonstrates improved thermodynamic stability over the cis isomer. The cis isoform (cis-palmitoleate) has been associated with increased insulin sensitivity and decreased lipid accumulation in the liver. Trans-palmitoleate is found in dairy products and partially hydrogenated oils and may be associated with favorable metabolic profiles and decreased incident diabetes.

The omega-7 fatty acid class includes, without limitation, 5-dodecenoic acid (12:1), 7-tetradecenoic acid (14:1), 9-hexadecenoic acid (palmitoleic acid) (16:1), 11-octadecenoic acid (vaccenic acid) (18:1), 9Z,11E-conjugated linoleic acid (rumenic acid) (18:2), 13-eicosenoic acid (paullinic acid) (20:1), 15-docosenoic acid (22:1), and 17-tetracosenoic acid (24:1).

Omega-7 fats are not essential fatty acids in humans, as they can be made endogenously. Both in plants and animals, palmitoleic acid is produced de novo by the Δ9 desaturation of palmitic acid. It is present in all tissues but, in general, is found in higher concentrations in the liver.

The historical identification of palmitoleic acid dates to the mid-nineteenth century. Palmitoleic acid (16 carbon atoms) was first noticed in 1854 by Hofstädter P.G. in sperm whale oil and named physetoleic acid; in 1906 Bull H. discovered its molecular composition, at which time Lewkowitsch gave the compound its present name; and the structure was established in 1925 by Armstrong E.F. et al.

2. Natural Sources

2.1 Plant Sources

Two plant sources having high concentrations of palmitoleic acid are sea buckthorn (Hippophae rhamnoides), which belongs to the Elaeagnaceae family and Rosales order, and macadamia nut oil (Macadamia integrifolia), which is native to Australia. Palmitoleic acid concentration in sea buckthorn is about 40%, and macadamia oil contains about 20%.

An important distinction exists between the two oil fractions produced from sea buckthorn berries. The most recognized product of sea buckthorn is its fruit oil, composed of seed oil that is rich in essential fatty acids, linoleic (18:2ω-6) and α-linolenic (18:3ω-3) acids, and pulp oil that contains high levels of monounsaturated palmitoleic acid (16:1ω-7). GC-MS profiling of fatty acids in seeds and pulp of berries indicated that the seed oil contained linoleic and α-linolenic acids at 33–36% and 30–36%, respectively, while the pulp oil contained palmitoleic acid at 32–42%. Therefore, for omega-7 content specifically, sea buckthorn pulp oil is the relevant fraction, not the seed oil.

A lesser but useful source of palmitoleic acid is avocado fruit (approximately 25,000 ppm).

2.2 Animal and Marine Sources

Animal sources of palmitoleic acid include certain fish oils, dairy fat, and human sebum, where palmitoleic acid is a natural component of the skin's lipid barrier. Mink oil contains about 15% palmitoleic acid. Some fish, such as anchovies and sardines, contain significant amounts of omega-7, in addition to other beneficial fatty acids such as omega-3.

Dairy products are one of the primary sources of dietary omega-7 fatty acids; however, the production of omega-7 fatty acids in cows is heavily diet-dependent. Dairy products contain vaccenic acid, which can be converted into palmitoleic acid by the body.

2.3 Endogenous Production

Palmitoleic acid is an omega-7 monounsaturated fatty acid (16:1n-7) found both in the diet and endogenously synthesized from palmitic acid via the enzyme stearoyl-CoA desaturase-1. Recognized as an adipokine, it is released from fat cells and influences various organs. Palmitoleic acid is not foreign to the human body: it is naturally present in the lipids of the skin and mucous membranes, where it contributes to barrier function, moisture retention, and tissue flexibility.

3. Common Forms and Preparations

Omega-7 is available commercially in several forms:

• Sea buckthorn pulp oil capsules: In the clinical literature, doses of 3 g of sea buckthorn oil per day have been studied in postmenopausal women over three-month interventions.
• Purified cis-palmitoleic acid capsules: These are concentrated extracts in which palmitoleic acid is isolated from marine or plant sources. The purified omega-7 fat used in some studies is derived from Peruvian anchovies and concentrated through a multi-step purification process to 50% palmitoleic acid.
• Algal-derived omega-7: Compositions rich in palmitoleic acid can be derived from algal sources, employing techniques such as transesterification of an algal lipid extract and distillation of the esterification product, followed by a crystallization step to isolate omega-7 products.
• Fish-oil concentrate (Alaska pollack): Some commercial preparations, such as 7-MEGA™, are food products made from purified Alaska pollack fish oil containing palmitoleic acid (16:1), commonly referred to as omega-7.
• Whole berry and juice preparations: Sea buckthorn berries are also consumed in the form of fresh berries, juice, or whole-berry powders, though the palmitoleic acid content of these preparations is lower and more variable than concentrated oil extracts.

There is no Recommended Daily/Dietary Allowance (RDA) for palmitoleate, which is not an essential fatty acid, meaning the body can produce it de novo.

4. Traditional and Historical Use

The traditional use of omega-7 as an isolated compound is, by necessity, a modern construct; pre-modern cultures used the whole plant or berry, of which omega-7 was an uncharacterized but active constituent. The primary vehicle of historical omega-7 exposure was Hippophae rhamnoides (sea buckthorn).

4.1 Tibetan Medicine (Sowa Rigpa)

Traditional use of sea buckthorn in Tibet goes back to the eighth century; the oily nature of the pulped berries was recognised as useful in treating sluggish, congested states with poor circulation and digestion. The sharp heat allocated to sea buckthorn berries in the Tibetan humoral medicinal classification of "Tarbu" gave the plant an expectorant action. In the traditional Tibetan healing system known as Sowa Rigpa, sea buckthorn was used as a natural remedy for respiratory problems, poor digestion, and skin issues, and was mentioned in texts around the 12th century AD for treating wounds and infections.

4.2 Traditional Chinese Medicine

The berries have been used for more than 2,000 years as a medicine and food additive in Europe, Russia, and Asia. Because of their hemostatic and anti-inflammatory effects, the fruits are added to prescriptions in Indian and Tibetan medicine to treat pulmonary, gastrointestinal, cardiac (e.g., ischemic heart disease), blood, hepatic, and metabolic disorders. In traditional Chinese medicine, sea buckthorn has been used to aid digestion and treat cough, circulatory disorders, and pain.

Sea buckthorn (Hippophae Fructus), as a homologous species of medicine and food, is widely used by Mongolians and Tibetans for its antitumor, antioxidant, and liver-protecting properties. China's National Health and Medical Commission has identified sea buckthorn among the traditional Chinese medicines that possess both nutritional and medicinal properties.

4.3 Ayurvedic and South Asian Traditions

Ancient Tibetan medical literature documents the use of sea buckthorn for fever, inflammation, toxicity, abscesses, cough, colds, clearing sputum, laxative purposes, tumors (particularly in the stomach and esophagus), and gynecological diseases. The flowers are used as a skin softener in Tajikistan. In Mongolia, extracts from the leaves and branches of the plant are used medicinally to treat colitis and enterocolitis in humans and animals.

In Ayurvedic texts, sea buckthorn is described as an adaptogen and "balancing dravya" for Vata and Pitta doshas, especially in high-altitude regions of India. In Tibetan medicine (Sowa Rigpa), sea buckthorn oil extracted from the seed was prized for treating lung ailments and digestive disorders, often administered as oil-pulling or decoctions.

4.4 Greek and European Traditions

The fruit also has a place in Greek history: according to mythology, it was fed to war horses after battles. The horses not only recovered faster but developed shiny coats, which is why the botanical name Hippophae means "shiny horse," and the fruit earned the nickname "The Warrior's Fruit." In Middle Asia, the leaves are used to treat gastrointestinal and skin disorders, and are topically applied to treat rheumatoid arthritis.

5. Key Constituents and Mechanisms of Action

5.1 Palmitoleic Acid as a Lipokine

The most scientifically significant mechanism identified for omega-7 is the role of palmitoleic acid as a lipokine — a lipid-derived hormone that acts on distant organs. Palmitoleic acid (POA), a nonessential monounsaturated omega-7 fatty acid (C16:1n7), is a lipid hormone secreted from adipose tissue and has beneficial effects on distant organs, such as the liver and muscle. Interestingly, POA decreases lipogenesis in toxic storage sites such as the liver and muscle, while paradoxically increasing lipogenesis in safe storage sites such as adipose tissue.

Palmitoleate was considered to be a lipokine based on evidence demonstrating its release from adipose tissue and its metabolic effects on distant organs. Following this finding, research has been conducted to determine whether palmitoleate has beneficial effects on metabolism and to elucidate the underlying mechanisms. In mice genetically deficient in fatty acid binding protein, palmitoleic acid released from adipose tissue was identified as a "lipokine" that promotes insulin action in muscle and suppresses hepatosteatosis and adipocyte cytokine expression.

Lipokine signaling decreases de novo lipogenesis in the liver, improves insulin sensitivity, and increases glucose uptake in the muscle. POA is synthesized both in adipose tissue and liver by the desaturase enzyme SCD-1; however, it is likely that POA synthesized in subcutaneous adipose tissue (as a lipokine) is the healthier signal and has beneficial pleiotropic effects.

5.2 Endocrine and Metabolic Signaling

Although the effects of palmitoleic acid are still debated, POA can regulate glucose homeostasis, lipid metabolism, and cytokine production, thus improving metabolic disorders. In animal models, cis-palmitoleate decreased the expression of proinflammatory markers and adipokines, which are related to the establishment of metabolic abnormalities.

Palmitoleic acid activates PPAR-α and PPAR-γ receptors, which reduce triglycerides and LDL cholesterol.

5.3 Pancreatic Beta-Cell Protection

Omega-7 fatty acids, especially palmitoleic acid, have been shown in vitro to decrease glucose-sensitive apoptosis in beta cells in the pancreas, a condition associated with diabetes. In adult organisms, new beta cells are most commonly the result of replication rather than direct stem cell differentiation, meaning that preventing apoptosis of beta cells is crucial for maintaining a stable beta-cell population. The cytoprotective effect of omega-7 fatty acids makes them a candidate for diabetes treatment.

5.4 Satiety Signaling

In animal studies, palmitoleic acid accumulated within the small intestine in a dose-dependent fashion and elevated levels of the satiety hormone cholecystokinin (CCK), affecting both protein and mRNA levels. The suppression of food intake by palmitoleic acid was attenuated by intravenous injection of devazepide, a selective peripheral CCK receptor antagonist.

5.5 Skin and Mucous Membrane Integration

Palmitoleic acid is naturally present in the lipids of the skin and mucous membranes, where it contributes to barrier function, moisture retention, and tissue flexibility. A unique property of palmitoleic acid is its ability to integrate into the epidermal lipid layer.

6. Scientific Evidence by Area of Use

6.1 Metabolic Syndrome and Insulin Sensitivity

Higher POA levels in humans are correlated with better insulin sensitivity, an improved lipid profile, and a lower incidence of type 2 diabetes and cardiovascular pathologies such as myocardial infarction. In preclinical animal models, POA improves glucose intolerance, dyslipidemia, and steatosis of the muscle and liver, while improving insulin sensitivity and secretion.

One notable epidemiological study examined the trans isoform specifically. Palmitoleic acid (cis-16:1n-7), which is produced by endogenous fat synthesis, has been linked to both beneficial and deleterious metabolic effects, potentially confounded by diverse determinants and tissue sources of endogenous production. Trans-palmitoleate (trans-16:1n-7) represents a distinctly exogenous source of 16:1n-7, unconfounded by endogenous synthesis, that may be uniquely informative. The objective was to investigate whether circulating trans-palmitoleate is independently related to lower metabolic risk and incident type 2 diabetes, in a prospective cohort study from 1992 to 2006 conducted in four U.S. communities among 3,736 adults in the Cardiovascular Health Study. During follow-up, individuals with higher circulating levels of trans-palmitoleic acid had about a 60 percent lower risk of developing diabetes among participants in the highest quintile of trans-palmitoleic acid levels, compared with individuals in the lowest quintile. The lead author noted that "this type of observational finding requires confirmation in additional observational studies and controlled trials."

A longitudinal observational study published in Diabetologia also investigated the relationship between circulating palmitoleate and insulin function. Plasma NEFA concentration and composition were determined in non-diabetic individuals from the Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) study cohort at baseline (n = 1,234) and after a three-year follow-up (n = 924); glucose tolerance, insulin secretion, and beta cell function were assessed during an OGTT, and whole-body insulin sensitivity was measured by a hyperinsulinaemic–euglycaemic clamp. The results supported the role of palmitoleate as a beneficial lipokine released by adipose tissue to prevent the negative effects of adiposity and excess NEFA on systemic glucose metabolism.

A protocol for a randomized placebo-controlled clinical trial using pure palmitoleic acid to ameliorate insulin resistance and lipogenesis in overweight and obese subjects with prediabetes has been published (Frontiers in Endocrinology, 2024), indicating that well-controlled human interventional trials in this area are still underway. Published review data have shown mixed cardiovascular effects, direct or inverse correlations with obesity and hepatosteatosis, but a significant amelioration or prevention of insulin resistance and diabetes.

Evidence strength: Mechanistic data (in vitro and animal) and large epidemiological studies are promising, but large-scale randomized controlled trials in humans confirming clinical benefit for insulin sensitivity and diabetes prevention remain limited or ongoing.

6.2 Cardiovascular Risk Markers (Lipids and Inflammation)

The most widely cited human RCT in this area was published in the Journal of Clinical Lipidology in 2014 (Bernstein, Roizen, Martinez). The study background noted that purified palmitoleic acid (16:1; omega-7) had shown lipid-lowering and anti-inflammatory benefits in open-label, epidemiological, and animal studies. Conclusions from the data indicated that purified palmitoleic acid may be useful in the treatment of hypertriglyceridemia with the beneficial added effects of decreasing LDL and hs-CRP and raising HDL; further study was called for to elucidate mechanisms and establish appropriate human doses. In that study, 30 days of supplementation with 210 mg/day of palmitoleic acid resulted in a significant drop in CRP of 1.9 mg/dL — a 43% reduction — with the average CRP level reduced from greater than 4 mg/dL to 2.1 mg/dL. Critically, this study was subsequently retracted. A retraction notice was issued for "Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled study" in the Journal of Clinical Lipidology, Volume 15, Issue 3 (May–June 2021). This retraction substantially weakens the direct interventional evidence for omega-7's effect on CRP and lipids.

A subsequent independent trial aimed to replicate these findings. In a crossover analysis (n = 50), three weeks of supplementation with an omega-7 fatty acid preparation containing 688 mg per day of palmitoleate did not reduce serum inflammatory biomarkers, nor did it improve subjectively measured quality of life compared to placebo. The investigators noted that future studies should explore appropriate biomarkers, sufficient power, length of dosing, inclusion criteria for volunteers with higher BMI, and verification of cis-palmitoleate versus trans-palmitoleate.

A separate large epidemiological study from the Cardiovascular Health Study (n = 3,630) examined the association between plasma phospholipid palmitoleic acid levels and cardiovascular risk markers. In multivariable analyses, higher palmitoleic acid concentrations were independently associated with lower LDL cholesterol (P < 0.001), higher HDL cholesterol (P < 0.001), lower total:HDL-cholesterol ratio (P = 0.04), and lower fibrinogen (P < 0.001).

Evidence strength: Epidemiological associations between circulating palmitoleate and favorable cardiovascular biomarkers are consistent across several large cohorts. However, the primary interventional RCT was retracted, and a replication trial failed to show anti-inflammatory effects. There is one well-designed RCT (Bernstein et al., 2014) showing impressive triglyceride and CRP reductions, plus strong mechanistic data from animal studies — but that trial has been retracted and large-scale human trials with cardiovascular endpoints are lacking. Evidence at this time must be regarded as preliminary.

6.3 Skin Health and Barrier Function

Several clinical trials have examined the effect of oral omega-7 supplementation on skin parameters. A randomized, double-blinded, placebo-controlled clinical study evaluated the efficacy and safety of oral palmitoleic acid in improving skin barrier, elasticity, and wrinkle formation in adult women. Ninety healthy participants were enrolled and received 500 mg/day palmitoleic acid (intervention) or corn oil without palmitoleic acid (control) for 12 weeks. Participants taking omega-7 experienced increased skin moisture levels along with reduced transepidermal water loss (TEWL) — a key indicator of skin barrier function — and measurements showed significant improvements in skin elasticity. No supplement-related adverse effects were reported.

A second RCT examined the omega-7 preparation 7-MEGA™. A total of 101 middle-aged females were randomly allocated to the intervention (N = 50) or placebo group (N = 51); each participant was advised to take either 500 mg of 7-MEGA™ or a placebo twice daily for 12 weeks. The primary outcomes were the degree of improvement in wrinkles and moisture filling; secondary outcomes included improvement in skin wrinkles, moisture changes at 4 and 8 weeks, changes in transdermal water loss, skin elasticity, the melanin index, the erythema index, and the Global Photo Damage Score.

Evidence strength: Multiple small but well-designed RCTs in women support improvements in skin hydration, TEWL, and elasticity with oral omega-7 supplementation over 12 weeks. Evidence is encouraging but limited to relatively small, short-duration studies.

6.4 Vaginal Atrophy and Menopausal Mucous Membrane Health

This is one of the areas where sea buckthorn oil (as an omega-7 vehicle) has the most consistent clinical evidence. A total of 116 postmenopausal women experiencing symptoms of vaginal dryness, itching, or burning were randomized to a placebo-controlled, double-blind study; 98 participants completed the intervention. Postmenopausal women took sea buckthorn oil or placebo daily for three months; sea buckthorn oil induced an improvement in the integrity of vaginal epithelium, and a beneficial trend on vaginal health index was observed in the sea buckthorn oil group. (Larmo et al., Maturitas, 2014; PMID 25104582.)

Consumption of sea buckthorn extract or oil may be beneficial for vaginal difficulties during menopause associated with vaginal atrophy and the thinning and drying of the vaginal mucosa. Menopausal women who used sea buckthorn oil had better vaginal epithelial integrity and a higher vaginal health score, and it has been proposed as an alternative to estrogen replacement therapy for postmenopausal women's vaginal health.

A vaginal gel containing sea buckthorn oil (Meclon Idra Alfasigma) has been studied in postmenopausal women to improve vaginal dryness, vaginal itching, burning sensation, dyspareunia, and vaginal pH.

Evidence strength: At least one well-designed, published, randomized placebo-controlled trial demonstrates improvement in vaginal epithelial integrity with sea buckthorn oil supplementation in postmenopausal women. The evidence is preliminary but is among the stronger areas of clinical research for this ingredient. The active role of palmitoleic acid (omega-7) specifically versus other constituents of sea buckthorn oil (carotenoids, sterols, tocopherols) cannot yet be isolated.

6.5 Dry Eye Syndrome

Studies show that the consumption of omega-7 (ω-7) improves the hydration of mucous membranes, including ocular mucous membranes. A randomized trial on dry eye syndrome required participants to take sea buckthorn seed oil capsules for six months. This study found that the sea buckthorn group had a big improvement in the stability of their tear film and their symptoms. (Larmo et al., J Nutr, 2010.)

Evidence strength: One well-designed RCT supports sea buckthorn oil for dry eye symptoms, but the active role of omega-7 as distinct from other lipid and antioxidant constituents of the oil is unclear.

6.6 Satiety and Food Intake

Analysis of the effect of palmitoleic acid on short-term food intake in male rats found that administration of omega-7 palmitoleic acid by oral gavage significantly decreased food intake compared to palmitic acid, omega-9 oleic acid, or a vehicle control. Palmitoleic acid exhibited a dose-dependent effect and did not cause general malaise. Orally administered palmitoleic acid induced satiety and enhanced the release of satiety hormones in rats.

Evidence strength: This evidence is entirely preclinical (animal studies). No human clinical trials on satiety have been identified in the published literature.

7. Body Systems and Health Areas of Association

• Metabolic/Endocrine System: Insulin sensitivity, glucose homeostasis, lipogenesis regulation, adipose-liver cross-talk via lipokine signaling. POA acts as a lipokine capable of influencing and modulating metabolic processes in adipose and other peripheral tissues by altering cytokine secretion and modulating circulating NEFA profiles.
• Cardiovascular System: Effects on circulating triglycerides, LDL, HDL, and inflammatory markers such as hs-CRP and fibrinogen, based on epidemiological and (now-retracted) interventional data.
• Integumentary System (Skin): Omega-7 fatty acids, mainly palmitoleic acid, may support skin barrier function. Multiple RCTs show improvements in skin hydration, elasticity, and TEWL.
• Reproductive/Urogenital System (Mucous Membranes): Sea buckthorn oil supplementation is associated with improvement in vaginal epithelial integrity and atrophy symptoms in postmenopausal women.
• Ocular System: Improvement in tear film osmolarity and dry eye symptoms with sea buckthorn oil supplementation.
• Gastrointestinal System: Historically used for digestive complaints and gastrointestinal disorders across multiple traditional medicine systems.
• Pancreatic Function: In vitro cytoprotective effects on insulin-secreting beta cells; no confirmed human clinical evidence for this mechanism.

8. Dosage Forms and Doses Reported in Studies

The following doses appear in the cited peer-reviewed clinical literature. They are reported here as observed in studies and do not constitute recommendations.

• Purified cis-palmitoleic acid (220.5 mg/day for 30 days): Used in the Bernstein et al. (2014) RCT examining CRP and serum lipid changes in adults with dyslipidemia and mild systemic inflammation. Note: This trial was retracted in 2021.
• Omega-7 mixed preparation (688 mg palmitoleate/day for 3 weeks): Used in a double-blind, placebo-controlled, 1:1 randomized single crossover trial, with an equivalent amount of medium-chain triglycerides for placebo.
• Sea buckthorn oil (3 g/day for 3 months): Used in the Larmo et al. (2014) vaginal atrophy RCT, in which participants consumed 3 g of sea buckthorn oil or placebo oil daily.
• Oral palmitoleic acid (500 mg/day for 12 weeks): Used in the Koh et al. (2023) skin barrier RCT (90 healthy participants, 500 mg/day palmitoleic acid versus corn oil for 12 weeks).
• 7-MEGA™ (500 mg twice daily for 12 weeks): Used in the anti-wrinkle RCT in 101 middle-aged females (50 mg of 7-MEGA™ or placebo twice daily for 12 weeks).
• General supplement range: Supplement doses in human studies commonly range from about 200 mg to 700 mg palmitoleic acid per day, or around 2 g per day of sea buckthorn oil, typically over 4–12 weeks.

9. Safety Considerations and Interactions

9.1 General Tolerability

In the 12-week Koh et al. skin barrier RCT, participants consumed 1,000 mg per day of an omega-7 concentrate (50% palmitoleic acid), and the study reported no supplement-related adverse effects, supporting safety and tolerability. Participants in previous studies have tolerated these oils well, with few side effects reported. Since the cardiovascular Phase 2 trial cited is in Phase 2, earlier studies have already assessed safety, indicating that palmitoleic acid is likely well-tolerated by healthy adults.

9.2 Palmitic Acid Contamination: A Specific Concern

A critical and source-backed safety consideration unique to omega-7 supplements relates to contamination by palmitic acid — a structurally similar but cardiovascularly unfavorable saturated fatty acid. Palmitic acid is not a favorable omega-7 fatty acid; according to the World Health Organization, evidence is "convincing" that consumption of palmitic acid (a saturated fatty acid) increases the risk of developing cardiovascular disease. Mensink et al. published a meta-analysis in the American Journal of Clinical Nutrition that clearly demonstrated palmitic acid raised low-density lipoprotein (LDL) cholesterol. Because palmitoleic acid and palmitic acid differ by only one double bond and co-occur in natural sources, impure preparations may contain meaningful amounts of palmitic acid. In one trial, the omega-7 verum contained 688 mg of 16:1n-7 fatty acid and 398 mg of palmitate per day. This highlights the importance of purification quality in commercial preparations.

9.3 Cis versus Trans Isomers

Future studies should explore the verification of cis-palmitoleate versus trans-palmitoleate, as the two isomers may have distinct biological effects and are present in different dietary sources. The endogenous production of palmitoleate by stearoyl-CoA desaturase 1 gives rise to its cis isoform, cis-palmitoleate. Although trans-palmitoleate is also synthesized in humans, it is mainly found as an exogenous source in ruminant fat and dairy products. Consumers and clinicians should be aware that supplement labels may not always specify which isomer is present.

9.4 Long-term Safety Data

Omega-7 supplements should be used cautiously in people with complex metabolic disease, pregnancy, or multiple medications, as long-term safety data are still limited. No long-term human safety trials have been published establishing a safe upper intake level.

9.5 Evidence Quality Issues

The retraction of the Bernstein et al. (2014) RCT — the single most-cited human interventional study in the omega-7 supplement field — is a significant caveat. The retraction notice was issued for "Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled study" in the Journal of Clinical Lipidology. Much of the commercial and popular literature citing omega-7 cardiovascular benefits is based on this retracted study; claims derived from it should be treated with particular caution.

9.6 Epidemiological Complexity

Palmitoleic acid (cis-16:1n-7), which is produced by endogenous fat synthesis, has been linked to both beneficial and deleterious metabolic effects, potentially confounded by diverse determinants and tissue sources of endogenous production. Elevated circulating palmitoleic acid can also reflect high endogenous de novo lipogenesis (itself a marker of metabolic dysfunction), which complicates the interpretation of observational data associating circulating palmitoleate with health outcomes.

References

• Wikipedia: Omega-7 fatty acid
• Wikipedia: Palmitoleic acid
• USPTO Patent 9200236: Omega 7 rich compositions and methods of isolating omega 7 fatty acids
• PMC3338740: Fatty Acid Composition of Developing Sea Buckthorn Berry and the Transcriptome of the Mature Seed
• PubMed 28096141: The Role of the Novel Lipokine Palmitoleic Acid in Health and Disease
• ScienceDirect: The Role of the Novel Lipokine Palmitoleic Acid in Health and Disease (full text)
• Frontiers in Endocrinology: Protocol for a randomized placebo-controlled clinical trial using pure palmitoleic acid — insulin resistance in prediabetes
• PMC9489414: The Different Insulin-Sensitising and Anti-Inflammatory Effects of Palmitoleic Acid and Oleic Acid in a Prediabetes Model
• Diabetologia: Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance
• PMC3537110: The Importance of Palmitoleic Acid to Adipocyte Insulin Resistance and Whole-Body Insulin Sensitivity in Type 1 Diabetes
• PubMed 23376733: Oral administration of omega-7 palmitoleic acid induces satiety and release of appetite-related hormones in male rats
• PubMed 25499944 / Retraction Notice: Purified palmitoleic acid for the reduction of hs-CRP and serum lipids (Bernstein et al., 2014; retracted 2021)
• PMC8398705: Omega-7 Mixed Fatty Acid Supplementation Fails to Reduce Serum Inflammatory Biomarkers: A Placebo-Controlled, Double-Blind Randomized Crossover Trial
• Annals of Internal Medicine: Trans-Palmitoleic Acid, Metabolic Risk Factors, and New-Onset Diabetes in U.S. Adults (Mozaffarian et al., 2010)
• PMC3056495: Trans-Palmitoleic Acid, Metabolic Risk Factors, and New-Onset Diabetes in US Adults (full text)
• PMC10245245: Efficacy and safety of oral palmitoleic acid supplementation for skin barrier improvement: A 12-week, randomized, double-blinded, placebo-controlled study (Koh et al., 2023)
• PMC10819616: Anti-Wrinkle and Skin Moisture Efficacy of 7-MEGA™: A Randomized, Double-Blind, Placebo Comparative Clinical Trial
• Maturitas: Effects of sea buckthorn oil intake on vaginal atrophy in postmenopausal women (Larmo et al., 2014)
• PMC10662087: Sea buckthorn, its bioactive constituents, and mechanism of action: potential application in female reproduction
• Drugs.com Natural Products Database: Sea Buckthorn Uses, Benefits & Dosage
• Herbal Reality: Sea Buckthorn (Hippophae rhamnoides): Benefits, Uses, Research
• Harvard Gazette: Dairy fat may help not harm (trans-palmitoleate and diabetes risk)
• ClinicalTrials.gov NCT02155816: Omega 7 + 3 Combination and Systemic Inflammation
• Vitamin Retailer: Palmitoleic Acid — An Omega-7 Fatty Acid for Inflammation & Metabolic Wellness